Biotransformation of Post-Clozapine Antipsychotics (Q30040355)

Europe PubMed Central

title

Biotransformation of Post-Clozapine Antipsychotics (English)

1 reference

24 May 2017

author name string

Silvio Caccia

series ordinal

1

1 reference

24 May 2017

publication date

May 2000

1 reference

Clinical Pharmacokinetics

24 May 2017

published in

1 reference

24 May 2017

volume

38

1 reference

24 May 2017

issue

5

1 reference

24 May 2017

page(s)

393-414

1 reference

The pharmacokinetics of remoxipride and metabolites in patients with various degrees of renal function

24 May 2017

cites work

1 reference

Crossref

https://api.crossref.org/works/10.2165%2F00003088-200038050-00002

Olanzapine Serum Concentrations in Psychiatric Patients Given Standard Doses: The Influence of Comedication

21 January 2018

1 reference

12 December 2020

Active metabolites of neuroleptics in plasma and CSF: implications for therapeutic drug monitoring

1 reference

12 December 2020

Identification of the major human liver cytochrome P450 isoform(s) responsible for the formation of the primary metabolites of ziprasidone and prediction of possible drug interactions

1 reference

12 December 2020

Olanzapine 10-N-glucuronide. A tertiary N-glucuronide unique to humans

1 reference

12 December 2020

Metabolism of phenothiazine and butyrophenone antipsychotic drugs. A review of some recent research findings and clinical implications

1 reference

12 December 2020

Identification of the human cytochromes P450 responsible for the in vitro formation of the major oxidative metabolites of the antipsychotic agent olanzapine.

1 reference

12 December 2020

Positron emission tomography studies on D2 dopamine receptor occupancy and plasma antipsychotic drug levels in man

1 reference

12 December 2020

Dopamine D4-like binding sites labeled by [3H]nemonapride include substantial serotonin 5-HT2A receptors in primate cerebral cortex.

1 reference

12 December 2020

In vivo effects of remoxipride and aromatic ring metabolites in the rat.

1 reference

12 December 2020

Binding characteristics of remoxipride and its metabolites to dopamine D2 and D3 receptors

1 reference

12 December 2020

Application of liquid chromatography/mass spectrometry in accelerating the identification of human liver cytochrome P450 isoforms involved in the metabolism of iloperidone

1 reference

12 December 2020

Brain extracellular levels of the putative antipsychotic CI-1007 and its effects on striatal and nucleus accumbens dopamine overflow in the awake rat.

1 reference

12 December 2020

Plasma level monitoring of antipsychotic drugs. Clinical utility

1 reference

12 December 2020

A pilot study on risperidone metabolism: the role of cytochromes P450 2D6 and 3A.

1 reference

12 December 2020

The emerging role of cytochrome P450 3A in psychopharmacology

1 reference

12 December 2020

Will routine therapeutic drug monitoring have a place in clozapine therapy?

1 reference

12 December 2020

Potential role of 5-HT2 and D2 receptor interaction in the atypical antipsychotic action of the novel succimide derivative, perospirone

1 reference

12 December 2020

Population pharmacokinetics of clozapine evaluated with the nonparametric maximum likelihood method

1 reference

12 December 2020

Metabolism and excretion of a new antipsychotic drug, ziprasidone, in humans

1 reference

12 December 2020

The use of atypical antipsychotics in the management of schizophrenia.

1 reference

12 December 2020

Atypical antipsychotics. Part I: Pharmacology, pharmacokinetics, and efficacy

1 reference

12 December 2020

Mode of action of tiaspirone on the central cholinergic system

1 reference

12 December 2020

Critical analysis and comparison of the side-effect and safety profiles of the new antipsychotics

1 reference

12 December 2020

Pharmacokinetics of clozapine and risperidone: a review of recent literature

1 reference

12 December 2020

3-Benzisothiazolylpiperazine derivatives as potential atypical antipsychotic agents.

1 reference

12 December 2020

In vivo neuropharmacology of schizophrenia

1 reference

12 December 2020

Racial and gender differences in N-acetyltransferase, xanthine oxidase, and CYP1A2 activities

1 reference

12 December 2020

Safety, tolerability, and effect of food on the pharmacokinetics of iloperidone (HP 873), a potential atypical antipsychotic

1 reference

12 December 2020

The time course of binding to striatal dopamine D2 receptors by the neuroleptic ziprasidone (CP-88,059-01) determined by positron emission tomography.

1 reference

12 December 2020

Succinimide derivatives. II. Synthesis and antipsychotic activity of N-[4-[4-(1,2-benzisothiazol-3-yl)-1-piperazinyl]butyl]-1,2-cis- cyclohexanedicarboximide (SM-9018) and related compounds

1 reference

12 December 2020

New antipsychotics: the present status

1 reference

12 December 2020

The metabolism and excretion of risperidone after oral administration in rats and dogs

1 reference

12 December 2020

Safety and pharmacokinetics of a single oral dose of amisulpride in healthy elderly volunteers.

1 reference

12 December 2020

Review of recent clinical studies with olanzapine

1 reference

12 December 2020

Influence of age, renal and liver impairment on the pharmacokinetics of risperidone in man.

1 reference

12 December 2020

Remoxipride: pharmacokinetics and effect on plasma prolactin

1 reference

12 December 2020

The involvement of CYP1A2 and CYP3A4 in the metabolism of clozapine

1 reference

12 December 2020

Localization and pharmacological characterization of [3H]perospirone-binding sites in rat brain.

1 reference

12 December 2020

Metabolism of the newer antidepressants. An overview of the pharmacological and pharmacokinetic implications

1 reference

12 December 2020

Synthesis and evaluation of heterocyclic carboxamides as potential antipsychotic agents

1 reference

12 December 2020

Risperidone dose and blood level variability: accumulation effects and interindividual and intraindividual variability in the nonresponder patient in the clinical practice setting

1 reference

12 December 2020

Ziprasidone and the pharmacokinetics of a combined oral contraceptive

1 reference

12 December 2020

Formation of active metabolites of psychotropic drugs. An updated review of their significance

1 reference

12 December 2020

Investigation of the CNS penetration of a potent 5-HT2a receptor antagonist (MDL 100,907) and an active metabolite (MDL 105,725) using in vivo microdialysis sampling in the rat.

1 reference

12 December 2020

Drug treatment of schizophrenia in the 1990s. Achievements and future possibilities in optimising outcomes

1 reference

12 December 2020

Predicting drug interactions and pharmacokinetic variability with in vitro methods: the olanzapine experience

1 reference

12 December 2020

Reversible metabolism of clozapine and clozapine N-oxide in schizophrenic patients

1 reference

12 December 2020

Psychopharmacology of olanzapine. A review.

1 reference

12 December 2020

Quetiapine : A Review of its Use in Schizophrenia

1 reference

12 December 2020

Clozapine and N-desmethylclozapine are potent 5-HT1C receptor antagonists.

1 reference

12 December 2020

In vitro metabolic interaction studies: experience of the Food and Drug Administration

1 reference

12 December 2020

Antipsychotic dosing strategies in acute schizophrenia.

1 reference

12 December 2020

Disposition and metabolism of olanzapine in mice, dogs, and rhesus monkeys

1 reference

12 December 2020

Biotransformation of the antipsychotic agent, mazapertine, in dog--mass spectral characterization and identification of metabolites

1 reference

12 December 2020

Pharmacokinetics and pharmacodynamics of clozapine

1 reference

12 December 2020

Therapeutic drug monitoring of risperidone using a new, rapid HPLC method: reappraisal of interindividual variability factors.

1 reference

12 December 2020

Active metabolites of neuroleptic drugs: possible contribution to therapeutic and toxic effects

1 reference

12 December 2020

Characterization of the novel benzisothiazole ring-cleaved products of the antipsychotic drug ziprasidone

1 reference

12 December 2020

An open study of tolerability and pharmacokinetics of raclopride extended release capsules in psychiatric patients: a Canadian study

1 reference

12 December 2020

Biotransformation of clozapine in humans

1 reference

12 December 2020

Pharmacokinetics of raclopride formulations. Influence of prolactin and tolerability in healthy male volunteers

1 reference

12 December 2020

Metabolism and excretion of the novel antipsychotic drug ziprasidone in rats after oral administration of a mixture of 14C- and 3H-labeled ziprasidone.

1 reference

12 December 2020

New antipsychotic medications: what advantages do they offer?

1 reference

12 December 2020

Olanzapine. A review of its pharmacological properties and therapeutic efficacy in the management of schizophrenia and related psychoses

1 reference

12 December 2020

Kinetic analysis of central [11C]raclopride binding to D2-dopamine receptors studied by PET--a comparison to the equilibrium analysis

1 reference

12 December 2020

Ziprasidone (CP-88,059): a new antipsychotic with combined dopamine and serotonin receptor antagonist activity

1 reference

12 December 2020

Plasma level monitoring of olanzapine in patients with schizophrenia: determination by high-performance liquid chromatography with electrochemical detection

1 reference

12 December 2020

The effect of carbamazepine on the steady-state pharmacokinetics of ziprasidone in healthy volunteers

1 reference

12 December 2020

Interaction of antipsychotic drugs with neurotransmitter receptor sites in vitro and in vivo in relation to pharmacological and clinical effects: role of 5HT2 receptors.

1 reference

12 December 2020

Do novel antipsychotics have similar pharmacological characteristics? A review of the evidence

1 reference

12 December 2020

Effects of gender and age on plasma levels of clozapine and its metabolites: analyzed by critical statistics

1 reference

12 December 2020

Survey on the pharmacodynamics of the new antipsychotic risperidone

1 reference

12 December 2020

JL13, a pyridobenzoxazepine compound with potential atypical antipsychotic activity: a review of its behavioural properties

1 reference

12 December 2020

Metabolism, pharmacogenetics, and metabolic drug-drug interactions of antipsychotic drugs

1 reference

12 December 2020

Distribution after repeated oral administration of different dose levels of risperidone and 9-hydroxy-risperidone in the brain and other tissues of rat.

1 reference

12 December 2020

High-performance liquid chromatographic determination of cis-N-(1-benzyl-2-methylpyrrolidin-3-yl)-5-chloro-2-methoxy-4- methylaminobenzamide in rat blood and brain using electrochemical detection

1 reference

12 December 2020

Pharmacological profile of risperidone

1 reference

12 December 2020

Ziprasidone and the activity of cytochrome P450 2D6 in healthy extensive metabolizers

1 reference

12 December 2020

Possible inhibitory effect of diazepam on the metabolism of zotepine, an antipsychotic drug.

1 reference

12 December 2020

Preclinical characterization of the potential of the putative atypical antipsychotic MDL 100,907 as a potent 5-HT2A antagonist with a favorable CNS safety profile

1 reference

12 December 2020

The effect of timing of a standard meal on the pharmacokinetics and pharmacodynamics of the novel atypical antipsychotic agent ziprasidone.

1 reference

12 December 2020

Regional brain distribution of risperidone and its active metabolite 9-hydroxy-risperidone in the rat.

1 reference

12 December 2020

Initial safety, tolerability pharmacodynamics, and pharmacokinetics of CI-1007 in patients with schizophrenia

1 reference

12 December 2020

Zotepine: preclinical tests predict antipsychotic efficacy and an atypical profile

1 reference

12 December 2020

Interindividual variations in human liver cytochrome P-450 enzymes involved in the oxidation of drugs, carcinogens and toxic chemicals: studies with liver microsomes of 30 Japanese and 30 Caucasians.

1 reference

12 December 2020

New antipsychotic agents with serotonin and dopamine antagonist properties based on a pyrrolo[2,1-b][1,3]benzothiazepine structure.

1 reference

12 December 2020

Pharmacokinetics of neuroleptics

1 reference

12 December 2020

Adverse effects of antipsychotic agents. Do newer agents offer advantages?

1 reference

12 December 2020

Cytochrome P450 2D6 genotype and steady state plasma levels of risperidone and 9-hydroxyrisperidone

1 reference

12 December 2020

Pharmacokinetics and pharmacodynamics of an investigational antipsychotic agent, CI-1007, in rats and monkeys.

1 reference

12 December 2020

Behavioural pharmacology of the new generation of antipsychotic agents

1 reference

12 December 2020

Risperidone: a novel antipsychotic with balanced serotonin-dopamine antagonism, receptor occupancy profile, and pharmacologic activity

1 reference

12 December 2020

Absorption, metabolism, and excretion of risperidone in humans.

1 reference

12 December 2020

In vivo occupation of dopamine D1, D2 and serotonin2A receptors by novel antipsychotic drug, SM-9018 and its metabolite, in rat brain

1 reference

12 December 2020

Quetiapine, an atypical antipsychotic

1 reference

12 December 2020

Olanzapine plasma concentrations and clinical response in acutely ill schizophrenic patients

1 reference

12 December 2020

Clinically significant pharmacokinetic drug interactions with psychoactive drugs: antidepressants and antipsychotics and the cytochrome P450 system

1 reference

12 December 2020

High-performance liquid chromatographic determination of nemonapride and desmethylnemonapride in human plasma using an electrochemical detection

1 reference

12 December 2020

Specific in vitro and in vivo binding of 3H-raclopride. A potent substituted benzamide drug with high affinity for dopamine D-2 receptors in the rat brain

1 reference

12 December 2020

Single- and multiple-dose pharmacokinetics of ziprasidone under non-fasting conditions in healthy male volunteers

1 reference

12 December 2020

Central 5-HT2A and D2 dopamine receptor occupancy after sublingual administration of ORG 5222 in healthy men.

1 reference

12 December 2020

Disposition of the antipsychotic agent CI-1007 in rats, monkeys, dogs, and human cytochrome P450 2D6 extensive metabolizers. Species comparison and allometric scaling

1 reference

12 December 2020

Single- and multiple-dose pharmacokinetics of ziprasidone in healthy young and elderly volunteers

1 reference

12 December 2020

Application of hyphenated LC/NMR and LC/MS techniques in rapid identification of in vitro and in vivo metabolites of iloperidone.

1 reference

12 December 2020

N(+)-glucuronidation of aliphatic tertiary amines in human: antidepressant versus antipsychotic drugs

1 reference

12 December 2020

Potential neuroleptic agents. 2,6-Dialkoxybenzamide derivatives with potent dopamine receptor blocking activities

1 reference

12 December 2020

Atypical antipsychotics: are some more atypical than others?

1 reference

12 December 2020

The pharmacological profile of iloperidone, a novel atypical antipsychotic agent

1 reference

12 December 2020

A critical assessment of antipsychotic drug monitoring

1 reference

12 December 2020

Identification of cytochrome P450 enzymes involved in the metabolism of zotepine, an antipsychotic drug, in human liver microsomes

1 reference

12 December 2020

Olanzapine: a new antipsychotic agent with efficacy in the management of schizophrenia

1 reference

12 December 2020

Comparative pharmacokinetics of a new benzamide neuroleptic drug in rats, dogs and monkeys using a stable isotope technique

1 reference

12 December 2020

Metabolism of the antipsychotic drug tiospirone in humans

1 reference

12 December 2020

Determination of CYP1A2 and NAT2 phenotypes in human populations by analysis of caffeine urinary metabolites.

1 reference

12 December 2020

Use of in vitro and in vivo data to estimate the likelihood of metabolic pharmacokinetic interactions

1 reference

12 December 2020

Drug metabolism and atypical antipsychotics

1 reference

12 December 2020

Pharmacokinetics and metabolism of 2-chloro-11-(2-dimethylaminoethoxy)-dibenzo[b,f]thiepine (zotepine) in rat, mouse, dog and man

1 reference

12 December 2020

The metabolism of atypical antipsychotic drugs: an update

1 reference

12 December 2020

Metabolism of risperidone to 9-hydroxyrisperidone by human cytochromes P450 2D6 and 3A4

1 reference

12 December 2020

Therapeutic drug monitoring for the treatment of psychiatric disorders. Clinical use and cost effectiveness

1 reference

12 December 2020

A pharmacological, pharmacokinetic and clinical overview of risperidone, a new antipsychotic that blocks serotonin 5-HT2 and dopamine D2 receptors.

1 reference

12 December 2020

Antipsychotic drugs. Clinical pharmacokinetics of potential candidates for plasma concentration monitoring

1 reference

12 December 2020

Remoxipride--a new potential antipsychotic compound. Tolerability and pharmacokinetics after single oral and intravenous administration in healthy male volunteers

1 reference

12 December 2020

Positron emission tomographic analysis of central 5-hydroxytryptamine2 receptor occupancy in healthy volunteers treated with the novel antipsychotic agent, ziprasidone.

1 reference

12 December 2020

Pharmacokinetics of the novel antipsychotic agent risperidone and the prolactin response in healthy subjects.

1 reference

12 December 2020

Regional distribution and in vivo binding of the atypical antipsychotic drug remoxipride. A biochemical and autoradiographic analysis in the rat brain

1 reference

12 December 2020

In vitro interaction of the antipsychotic agent olanzapine with human cytochromes P450 CYP2C9, CYP2C19, CYP2D6 and CYP3A

1 reference

12 December 2020

A comparative review of new antipsychotics

1 reference

12 December 2020

Incremental dosage of the new antipsychotic mazapertine induces tolerance to cardiovascular and cognitive effects in healthy men.

1 reference

12 December 2020

Time course of central nervous dopamine-D2 and 5-HT2 receptor blockade and plasma drug concentrations after discontinuation of quetiapine (Seroquel) in patients with schizophrenia

1 reference

12 December 2020

Drug interactions with tobacco smoking. An update

1 reference

12 December 2020

Cytochrome P450 3A: ontogeny and drug disposition

1 reference

12 December 2020

Orally active benzamide antipsychotic agents with affinity for dopamine D2, serotonin 5-HT1A, and adrenergic alpha1 receptors

1 reference

12 December 2020

Positron emission tomographic analysis of dose-dependent MDL 100,907 binding to 5-hydroxytryptamine-2A receptors in the human brain

1 reference

12 December 2020

The new selective D2-dopamine receptor antagonist raclopride--pharmacokinetics, safety and tolerability in healthy males

1 reference

12 December 2020

The pharmacokinetics of ziprasidone in subjects with normal and impaired hepatic function

1 reference

12 December 2020

Effects of amperozide in schizophrenia. An open study of a potent 5-HT2 receptor antagonist

1 reference

12 December 2020

Picogram determination of iloperidone in human plasma by solid-phase extraction and by high-performance liquid chromatography—selected-ion monitoring electrospray mass spectrometry

1 reference

12 December 2020

Atypical antipsychotics: Part II: Adverse effects, drug interactions, and costs

1 reference

12 December 2020

New atypical antipsychotics. Experience and utility in the elderly

1 reference

12 December 2020

Comparison of [3H]YM-09151-2 with [3H]spiperone and [3H]raclopride for dopamine d-2 receptor binding to rat striatum

1 reference

12 December 2020

Amisulpride: from animal pharmacology to therapeutic action

1 reference

12 December 2020

Pharmacokinetics and drug interactions: update for new antipsychotics

1 reference

12 December 2020

Biotransformation of trans-5-chloro-2-methyl-2,3,3a,12b-tetrahydro-1-H-dibenz[2,3:6,7]oxepin o [4,5-c]pyrrolidine maleate in rats

1 reference

12 December 2020

The effects of ketoconazole on ziprasidone pharmacokinetics--a placebo-controlled crossover study in healthy volunteers

1 reference

12 December 2020

Iloperidone binding to human and rat dopamine and 5-HT receptors

1 reference

12 December 2020

Olanzapine. Pharmacokinetic and pharmacodynamic profile.

1 reference

12 December 2020

Stereospecific determination of amisulpride, a new benzamide derivative, in human plasma and urine by automated solid-phase extraction and liquid chromatography on a chiral column. application to pharmacokinetics

1 reference

12 December 2020

Single oral dose kinetics of zotepine and its relationship to prolactin response and side effects

1 reference

12 December 2020

Disposition and biotransformation of the antipsychotic agent olanzapine in humans

1 reference

12 December 2020

Determination of amisulpride, a new benzamide derivative, in human plasma and urine by liquid-liquid extraction or solid-phase extraction in combination with high-performance liquid chromatography and fluorescence detection. application to pharmacok

1 reference

12 December 2020

Synthesis and biological activity of the putative metabolites of the atypical antipsychotic agent tiospirone

1 reference

12 December 2020

D2 and 5-HT2 receptor effects of antipsychotics: bridging basic and clinical findings using PET.

1 reference

12 December 2020

The pharmacokinetics of ziprasidone in subjects with normal and impaired renal function

1 reference

12 December 2020

A PET study of D2 and 5-HT2 receptor occupancy induced by risperidone in poor metabolizers of debrisoquin and risperidone

1 reference

12 December 2020

Neutrophil cytotoxicity of the chemically reactive metabolite(s) of clozapine: possible role in agranulocytosis

1 reference

12 December 2020

1 reference

12 December 2020

10.2165/00003088-200038050-00002

Identifiers

DOI

1 reference